Patents by Inventor Stewart Campbell

Stewart Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052503
    Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.
    Type: Application
    Filed: November 5, 2020
    Publication date: February 25, 2021
    Applicant: Axial Therapeutics, Inc.
    Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
  • Publication number: 20210017166
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: February 24, 2020
    Publication date: January 21, 2021
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • Publication number: 20200390809
    Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
    Type: Application
    Filed: March 23, 2020
    Publication date: December 17, 2020
    Applicant: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, David H. Donabedian
  • Publication number: 20200368276
    Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
    Type: Application
    Filed: June 10, 2020
    Publication date: November 26, 2020
    Inventors: Anthony Stewart Campbell, David H. Donabedian
  • Publication number: 20200290970
    Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.
    Type: Application
    Filed: August 6, 2018
    Publication date: September 17, 2020
    Applicant: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
  • Publication number: 20200163933
    Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
    Type: Application
    Filed: May 14, 2018
    Publication date: May 28, 2020
    Inventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
  • Patent number: 10617718
    Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: April 14, 2020
    Assignee: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, David H. Donabedian
  • Patent number: 10570123
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 25, 2020
    Assignee: SURFACE LOGIX, LLC
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • Publication number: 20190367272
    Abstract: There is provided a picking cart having an information communication device for communicating information relating to an article to be picked and a weighing device for measuring a weight of the article to be picked. The picking cart further has a power distribution system that is configured to power the information communication device by a first battery and the weighing device by the first battery or a second battery. The weighing device is powered by the first battery in preference to the second battery if a charge of the second battery is less than or equal to a first threshold amount.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 5, 2019
    Inventors: Stewart Campbell, Paul Steven Hines
  • Publication number: 20190233268
    Abstract: Systems and methods for mobile dimensioning and weighing are disclosed. An example mobile weighting and dimensioning system includes a truck scale system and a tape measure. The truck scale system includes: a fork scale to weigh a parcel that is held by forks; and a weight indicator to receive an indication of the weight of the parcel from the fork scale. The tape measure includes: a tape cartridge to spool and unspool a tape having electronically readable indicia; a measurement circuit to determine linear dimensions of the parcel by reading the electronically readable indicia in response to trigger events; and a communications circuit to transmit the first linear dimension of the parcel to the weight indicator. The weight indicator associates the weight and the first linear dimension with an identifier of the parcel, and transmits the weight, the first linear dimension, and the identifier to a computing system.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 1, 2019
    Inventors: Stewart Campbell, Paul Steven Hines
  • Publication number: 20190177311
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: July 19, 2018
    Publication date: June 13, 2019
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshardri
  • Publication number: 20180303876
    Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
    Type: Application
    Filed: May 31, 2018
    Publication date: October 25, 2018
    Applicant: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, David H. Donabedian
  • Publication number: 20180072710
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: April 24, 2017
    Publication date: March 15, 2018
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshardri
  • Patent number: 9656960
    Abstract: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: May 23, 2017
    Assignee: Surface Logix, Inc.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Enoch Kim, Paul Sweetnam, Yingfei Yang
  • Publication number: 20160375120
    Abstract: The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 29, 2016
    Inventors: A. Stewart Campbell, Gregory Lohman, Obadiah Joseph Plante
  • Patent number: 9447133
    Abstract: The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: September 20, 2016
    Assignee: VISTERRA, INC.
    Inventors: A. Stewart Campbell, Gregory Lohman, Obadiah J. Plante
  • Patent number: 9440961
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: September 13, 2016
    Assignee: SURFACE LOGIX, INC.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • Publication number: 20160144016
    Abstract: The present invention provides synthetic Pseudomonas aeruginosa lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various P. aeruginosa serotype-specific oligosaccharide antigens or various core P. aeruginosa oligosaccharide structures or motifs. The invention further provides P. aeruginosa LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by P. aeruginosa.
    Type: Application
    Filed: July 1, 2014
    Publication date: May 26, 2016
    Applicant: SynGlyco Pharmaceuticals, Inc.
    Inventors: A. Stewart Campbell, Obadiah Joseph Plante
  • Publication number: 20160039765
    Abstract: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.
    Type: Application
    Filed: March 17, 2015
    Publication date: February 11, 2016
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Enoch Kim, Paul Sweetnam, Yingfei Yang
  • Publication number: 20150344464
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: December 23, 2014
    Publication date: December 3, 2015
    Inventors: ALESSANDRA BARTOLOZZI, STEWART CAMPBELL, HOPE FOUDOULAKIS, BRIAN KIRK, SIYA RAM, PAUL SWEETNAM